New Study Identifies Mechanism to End Inflammation and Its Implications for Health
Researchers at University College London (UCL) have identified a biological mechanism that helps the body bring inflammation to an end, a finding that could eventually lead to new treatments for chronic inflammatory diseases affecting millions of people. Inflammation is one of the immune system's most important defense responses. It helps the body fight infection and repair damaged tissue. However, if that response remains active for too long, it can begin to harm healthy tissue and contribute to conditions such as arthritis, heart disease, and diabetes.
While scientists have long understood how inflammation begins, the process by which the body determines that the danger has passed and shifts from fighting a threat to repairing the damage has been less clear. The new study, published in Nature Communications, points to a group of small fat-derived molecules called epoxy-oxylipins as part of that shutdown process. According to the researchers, these molecules act like natural brakes on the immune system, helping to prevent excessive growth of intermediate monocytes, a type of white blood cell that can support healing in the short term but may contribute to chronic inflammation if too many accumulate or remain active for too long.
To study the process directly in humans, the researchers administered a tiny injection of UV-killed E. coli bacteria into the forearm of healthy volunteers. Although the bacteria were no longer alive and could not cause an infection, they still triggered a temporary inflammatory response, producing familiar signs of inflammation such as pain, redness, heat, and swelling, similar to what occurs after an injury or infection. The volunteers were divided into two groups: a prophylactic arm and a therapeutic arm.
Participants received a drug called GSK2256294 at different stages of the inflammatory response. This drug blocks an enzyme known as soluble epoxide hydrolase (sEH), which normally breaks down epoxy-oxylipins. By blocking this enzyme, the researchers aimed to increase the levels of these protective molecules in the body.
Both approaches produced similar results. Blocking sEH increased epoxy-oxylipin levels, helped pain resolve more quickly, and sharply reduced the number of intermediate monocytes found in both the blood and tissue. These immune cells are linked to persistent inflammation and the progression of inflammatory diseases. However, the treatment did not significantly change visible signs such as redness or swelling, suggesting that the drug may have altered deeper immune processes even when outward symptoms remained largely unchanged.
The researchers investigated the mechanism at the molecular level and found that one epoxy-oxylipin, 12,13-EpOME, appears to suppress a protein signaling pathway known as p38 MAPK, which drives the transformation of monocytes into the intermediate form associated with prolonged inflammatory activity. The team confirmed this mechanism in laboratory experiments and in volunteers who received a drug that directly blocks p38.
First author Dr. Olivia Bracken from the UCL Department of Ageing, Rheumatology and Regenerative Medicine stated, "Our findings reveal a natural pathway that limits harmful immune cell expansion and helps calm inflammation more quickly. Targeting this mechanism could lead to safer treatments that restore immune balance without suppressing overall immunity. With chronic inflammation ranked as a major global health threat, this discovery opens a promising avenue for new therapies."
Many existing treatments for inflammatory and autoimmune diseases work by suppressing parts of the immune system. While this can reduce inflammation, it may also interfere with the body's ability to defend itself. The pathway identified in this study may offer another strategy: strengthening a natural process the body already uses to bring inflammation under control. Corresponding author Professor Derek Gilroy from the UCL Division of Medicine noted, "This is the first study to map epoxy-oxylipin activity in humans during inflammation. By boosting these protective fat molecules, we could design safer treatments for diseases driven by chronic inflammation."
The study was funded by Arthritis UK and involved researchers from UCL, King's College London, University of Oxford, Queen Mary University of London, and the National Institute of Environmental Health Sciences in the USA. The findings could pave the way for clinical trials testing sEH inhibitors in chronic inflammatory conditions, including rheumatoid arthritis and cardiovascular disease. Dr. Bracken added, "For instance, rheumatoid arthritis is a condition in which the immune system attacks the cells that line your joints. sEH inhibitors could be trialed alongside existing medications to investigate if they can help prevent or slow down joint damage incurred by the condition."
Dr. Caroline Aylott, Head of Research Delivery at Arthritis UK, emphasized the importance of this research, stating, "The pain of arthritis can affect how we move, think, sleep, and feel, along with our ability to spend time with loved ones. Pain is incredibly complex and is affected by many different factors. We also know that everybody's pain is different. That is why it is important that we invest in research like this, that helps us understand what causes and influences people's experience of pain. We are excited to see the results of this study, which has found a natural process that could stop inflammation and pain. We hope in the future that this will lead to new pain management options for people with arthritis."
The study highlights the potential for new therapeutic strategies that leverage the body's natural mechanisms to manage inflammation, offering hope for improved treatments for those suffering from chronic inflammatory diseases.




